Sagimet Biosciences Inc. 8-K

What Happened
Sagimet Biosciences Inc. filed a Form 8-K on February 2, 2026 (Item 7.01) to disclose that Ascletis Pharma Inc. announced on January 29, 2026 positive topline results from an open‑label Phase 3 trial evaluating the long‑term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Sagimet furnished its press release announcing this news and an updated investor slide presentation as exhibits to the 8-K. Company representatives said they will use the updated presentation in investor meetings.

Key Details

• Ascletis announcement date: January 29, 2026 — positive topline results from an open‑label Phase 3 long‑term safety trial.
• Drug: ASC40 (denifanstat) tablets, studied in patients with moderate to severe acne.
• Sagimet filings: press release (Exhibit 99.1) and updated investor presentation (Exhibit 99.2) attached to the 8‑K filed February 2, 2026.
• Disclosure made under Regulation FD (Item 7.01); no new financial statements or officer changes reported in this filing.

Why It Matters
This 8‑K updates investors on clinical progress for ASC40, a compound relevant to Sagimet’s pipeline/partnership interests. Positive topline Phase 3 safety results from Ascletis are material operational news that the company has publicly disclosed and incorporated into investor materials. Investors tracking Sagimet for clinical milestones, licensing potential, or partnership value should note the announcement and review the furnished press release and slides for details.